featured
Chemotherapy De-Escalation Using an 18F-FDG PET–Based Pathological Response–Adapted Strategy in Patients With HER2-Positive Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Chemotherapy De-Escalation Using an 18F-FDG-PET-Based Pathological Response-Adapted Strategy in Patients With HER2-Positive Early Breast Cancer (PHERGain): A Multicentre, Randomised, Open-Label, Non-Comparative, Phase 2 Trial
Lancet Oncol 2021 Jun 01;22(6)858-871, JM Pérez-García, G Gebhart, M Ruiz Borrego, A Stradella, B Bermejo, P Schmid, F Marmé, S Escrivá-de-Romani, L Calvo, N Ribelles, N Martinez, C Albacar, A Prat, F Dalenc, K Kerrou, M Colleoni, N Afonso, S Di Cosimo, M Sampayo-Cordero, A Malfettone, J Cortés, A Llombart-CussacFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.